Switzerland-based Kuros Biosciences AG has appointed Pascal Longlade as chief medical officer to help oversee the development of its products for tissue repair and regeneration. Kuros was created in 2015 from a reverse merger with the asthma drug developer Cytos Biotechnology Ltd.
Dr Longlade was previously director of medical affairs at D&A Pharma SAS and before that, CMO at Trophos SA, a developer of treatments for neuromuscular diseases which was acquired by Roche in 2015. During his career, Dr Longlade spent 10 years in clinical medicine and holds a MD from Lariboisière-Saint-Louis Medical School in Paris, France.
Kuros Biosciences announced the appointment on 23 August 2018.
Copyright 2018 Evernow Publishing Ltd.